

***Fiscal Year 2021 (FY21) Peer Reviewed Alzheimer’s Research Program (PRARP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Convergence Science Research Award:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-21-PRARP-CSRA</p>	<p>Level I: Investigators at the postdoctoral level (e.g., research associates, fellows, medical residents, or equivalent) but below the level of Assistant Professor (or equivalent) at the time of the application submission deadline.</p> <ul style="list-style-type: none"> • Mentor required. <p>Level II: The Principal Investigator (PI) must be an independent investigator at or above the level of Assistant Professor (or equivalent) at the time of the application submission deadline.</p>	<p>Intent: To support innovative and impactful efforts to generate research resources, tools, and new avenues of investigation for researchers and practitioners in the health sciences.</p> <ul style="list-style-type: none"> • Level I: Applicant can be from any field or discipline and must write the project narrative and other application components, with appropriate guidance from the mentor(s). The mentor(s) must possess qualifications, background, and experience in both the identified military risk factor and Alzheimer’s disease (AD)/AD-related dementias (ADRD) research. • Level II: Intended to support applicants from any field or discipline at or above the level of assistant professor (or equivalent) from any field or discipline. Study teams are expected to demonstrate relevant experience in both the identified military risk factor and AD/ADRD. <p>Applications must address one of the following FY21 PRARP Overarching Challenges:</p> <ul style="list-style-type: none"> • Foundational Research • Paucity of Clinical Studies • Diagnostics and Prognostics • Epidemiology <p>Applications should address one of the following FY21 PRARP Military Risk Factors:</p> <ul style="list-style-type: none"> • Traumatic Brain Injury • Neurophysiological/Neurobehavioral • Vascular • Inflammation • Genetic 	<p>Level I:</p> <ul style="list-style-type: none"> • Maximum funding of \$225,000 for direct costs (plus indirect costs). • Maximum period of performance is 3 years. <p>Level II:</p> <ul style="list-style-type: none"> • Maximum funding of \$500,000 for direct costs (plus indirect costs). • Maximum period of performance is 3 years. <p>For Both Levels: Indirect costs may be proposed in accordance with the institution’s rate agreement.</p>	<p>Pre-Application (Letter of Intent): June 14, 2021, 5:00 p.m. Eastern time (ET)</p> <p>Application: July 21, 2021, 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
		<ul style="list-style-type: none"> • Metabolic • Sleep <p>Pharmacological interventions are specifically discouraged.</p> <p>While not required, applications to either Funding Level I or II are encouraged to provide relevant preliminary data.</p> <p>Research that focuses exclusively on chronic traumatic encephalopathy (CTE) research is prohibited.</p>		
<p>Innovation in Care and Support Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-21-PRARP-InCASA</p>	<p>Level I: Investigators at the postdoctoral level (e.g., research associates, fellows, medical residents, or equivalent) but below the level of Assistant Professor (or equivalent) at the time of the application submission deadline.</p> <ul style="list-style-type: none"> • Mentor required. <p>Level II: The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent) at the time of the application submission deadline.</p>	<p>Intent: To support innovative and impactful research that improves the quality of life and care for individuals, families, and care providers living with AD/ADRD.</p> <ul style="list-style-type: none"> • Level I: Applicant can be from any field or discipline and must write the project narrative and other application components, with appropriate guidance from the mentor(s). The mentor(s) must possess qualifications, background, and experience in both the identified military risk factor and AD/ADRD. • Level II: Intended to support applicants from any field or discipline at or above the level of assistant professor (or equivalent) from any field or discipline. Study teams are expected to demonstrate relevant experience in both the identified military risk factor and AD/ADRD. <p>Applications must address one of the following FY21 PRARP Overarching Challenges:</p> <ul style="list-style-type: none"> • Paucity of Clinical Studies • Quality of Life • Family and Care Support 	<p>Level I:</p> <ul style="list-style-type: none"> • Maximum funding of \$225,000 for direct costs (plus indirect costs). • Maximum period of performance is 3 years. <p>Level II:</p> <ul style="list-style-type: none"> • Maximum funding of \$500,000 for direct costs (plus indirect costs). • Maximum period of performance is 3 years. <p>For Both Levels: Indirect costs may be proposed in accordance with the institution's rate agreement.</p>	<p>Pre-Application (Letter of Intent): June 14, 2021, 5:00 p.m. ET</p> <p>Application: July 21, 2021, 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
		<p>Applications should address one of the following FY21 PRARP Military Risk Factors:</p> <ul style="list-style-type: none"> • Traumatic Brain Injury • Neurophysiological/Neurobehavioral • Modifiable Risk Factors • Vascular • Inflammation • Genetic • Metabolic • Sleep <p>Pharmacological interventions are specifically discouraged.</p> <p>Animal research is prohibited.</p> <p>While not required, applications to either Funding Level I or II are encouraged to provide relevant preliminary data.</p> <p>Research that focuses exclusively on CTE research is prohibited.</p>		
<p>Research Partnership Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-21-PRARP-RPA</p>	<p>The initiating PI must be an independent investigator at or above the level of Assistant Professor (or equivalent) at the time of the application submission deadline.</p> <p>Each named Co-PI must be at or above the level of assistant professor (or equivalent) at the time of the application submission deadline.</p>	<p>Intent: To create an avenue for collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts as related to the PRARP’s mission.</p> <p>Applications must include clearly stated plans for interactions between/among the partners. The plans must include communication, decision-making, allocation of resources, coordination of research progress and results, and sharing of data among all investigators and organizations participating in the project.</p>	<ul style="list-style-type: none"> • Funding limit is \$1.3 million (M) in total costs. • Maximum period of performance is 3 years. • Indirect costs may be proposed in accordance with the institution’s rate agreement. 	<p>Pre-Application (Letter of Intent):</p> <p>June 14, 2021, 5:00 p.m. ET</p> <p>Application:</p> <p>July 21, 2021, 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
		<p>Applications must address one of the following FY21 PRARP Overarching Challenges:</p> <ul style="list-style-type: none"> • Foundational Research • Paucity of Clinical Studies • Diagnostics and Prognostics • Epidemiology • Quality of Life • Family and Care Support <p>Applications should address at least one of the following FY21 PRARP Military Risk Factors:</p> <ul style="list-style-type: none"> • Traumatic Brain Injury • Neurophysiological/Neurobehavioral • Modifiable Risk Factors • Vascular • Inflammation • Genetic • Metabolic • Sleep <p>Pharmacological interventions are specifically discouraged.</p> <p>Preliminary data to support the feasibility of the research hypothesis (or hypotheses) or objectives are required.</p> <p>Research that focuses exclusively on CTE research is prohibited.</p>		
<p>Accelerating Diagnostic Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions 	<p>The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent) at the time of the application submission deadline.</p>	<p>Intent: To support high-impact, human-based development of robust diagnostic and/or prognostic biomarkers for military risk factors that pertain to AD/ADRD.</p> <p>Applications must address the following FY21 PRARP Overarching Challenge.</p> <ul style="list-style-type: none"> • Diagnostics and Prognostics 	<ul style="list-style-type: none"> • Funding limit is \$2.8M in total costs. • Maximum period of performance is 4 years. • Indirect costs may be proposed in 	<p>Pre-Application (Letter of Intent):</p> <p>June 14, 2021, 5:00 p.m. ET</p> <p>Application:</p> <p>July 21, 2021,</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Grants.gov Funding Opportunity Number: W81XWH-21-PRARP-ADRA</p>		<p>Applications must address one of the following FY21 PRARP Military Risk Factors:</p> <ul style="list-style-type: none"> • Traumatic Brain Injury • Neurophysiological/Neurobehavioral • Vascular • Inflammation • Genetic • Metabolic <p>The proposed biomarker for investigation must correlate with clinical endpoints to include cognition and/or behavior relevant to the proposed military risk factor and AD/ADRD. The applicant must choose one biomarker category for the overall application:</p> <ul style="list-style-type: none"> • Imaging-Related • Fluid-Based (e.g., cerebrospinal fluid, blood, or saliva) • Retinal • Wearable Devices • Other <p>Studies focused on biomarker discovery are discouraged.</p> <p>Pharmacological interventions are specifically discouraged.</p> <p>Animal research is prohibited.</p> <p>Preliminary data regarding the suitability of the biomarker(s) for further testing toward biomarker qualification is <i>required</i>.</p> <p>Research that focuses exclusively on CTE research is prohibited.</p>	<p>accordance with the institution's rate agreement.</p>	<p>11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Leveraging Approaches for Innovation in Care and Support Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-21-PRARP-LEAP-InCASA</p>	<p>The Coordinating Center PI must be at or above the level of assistant professor (or equivalent) at the time of the application submission deadline.</p> <p>Each named Partnering Site PI must be at or above the level of an assistant professor (or equivalent) at the time of the application submission deadline.</p>	<p>Intent: To support innovative and impactful research that improves the quality of life and care for individuals, families, and care providers living with AD/ADRD.</p> <p>Applications must address one of the following FY21 PRARP Overarching Challenges:</p> <ul style="list-style-type: none"> • Quality of Life • Family and Care Support <p>Applications should address one of the following FY21 PRARP Military Risk Factors:</p> <ul style="list-style-type: none"> • Traumatic Brain Injury • Neurophysiological/Neurobehavioral • Modifiable Risk Factors • Vascular • Inflammation • Genetic • Metabolic • Sleep <p>Requires a Coordinating Center and at least two Partnering Sites.</p> <ul style="list-style-type: none"> • The Coordinating Center provides overall leadership and management infrastructure for all research initiatives. • Each Partnering Site should develop its own unique research initiative as relevant to the overall application design. • The Coordinating Center participates as a separate study arm for each Partnering Site’s study. • Coordinating and Partnering Sites work together to harmonize research protocols, develop participant accrual strategies, and analyze data. • Plans for interactions between/among the partners should be well detailed and must include communication, decision-making, allocation of 	<ul style="list-style-type: none"> • Funding limit is \$2.8M in total costs. • Maximum period of performance is 4 years. <p>Indirect costs may be proposed in accordance with the institution’s rate agreement.</p>	<p>Pre-Application (Letter of Intent):</p> <p>June 14, 2021, 5:00 p.m. ET</p> <p>Application:</p> <p>July 21, 2021, 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
		<p>resources, and coordination of research progress and results among all Partnering Sites.</p> <ul style="list-style-type: none"> • Each Partnering Site should detail a research initiative that is unique from the other Partnering Sites. <p>The Coordinating Center applicant organization will submit and the individual named as the PI in the application will be designated as the PI; the other partner(s) will be designated as the Co-PI(s).</p> <p>The Coordinating Center must be from a different institution than the Partnering Sites.</p> <p>The Partnering Sites Applicant Organizations must be from different institutions.</p> <p>Pharmacological interventions are specifically discouraged.</p> <p>Animal research is prohibited.</p> <p>Preliminary data to support the feasibility of the research hypothesis (or hypotheses) or objectives are <i>required</i>.</p> <p>Research that focuses exclusively on CTE research is prohibited.</p>		